Literature DB >> 30846029

Autoimmune Diseases of the Biliary Tract: A Review.

Christina W Lee1, Sean Ronnekleiv-Kelly2.   

Abstract

The management of autoimmune hepatobiliary disorders remains a challenging and emerging area of investigation. An awareness of cholestatic liver diseases is critical to appropriate recognition and management of these challenging diseases, because patients often present asymptomatically, and diagnosis is limited by the lack of disease-specific markers and diagnostic studies. Furthermore, there is a paucity of treatment options because the pathophysiology underlying autoimmune biliary diseases remains largely unknown. This article discusses the natural history, clinical presentation, diagnosis, and medical and surgical management strategies for three dominant autoimmune biliary diseases: primary biliary cirrhosis, primary sclerosing cholangitis, and immunoglobulin G4-related hepatobiliary disease. Published by Elsevier Inc.

Entities:  

Keywords:  Biliary tract; IgG4-related sclerosing cholangitis; Primary biliary cirrhosis; Primary sclerosing cholangitis

Mesh:

Year:  2019        PMID: 30846029     DOI: 10.1016/j.suc.2018.11.003

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  4 in total

Review 1.  The NOD Mouse Beyond Autoimmune Diabetes.

Authors:  Anne-Marie Aubin; Félix Lombard-Vadnais; Roxanne Collin; Holly A Aliesky; Sandra M McLachlan; Sylvie Lesage
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

2.  Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice.

Authors:  Vik Meadows; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Fanyin Meng; Shohaib Virani; Evan Reinhart; Konstantina Kyritsi; Pietro Invernizzi; Zhihong Yang; Nan Wu; Suthat Liangpunsakul; Gianfranco Alpini; Heather Francis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-09-13       Impact factor: 5.187

3.  Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.

Authors:  Lindsey Kennedy; Vik Meadows; Jennifer Demieville; Laura Hargrove; Shohaib Virani; Shannon Glaser; Tianhao Zhou; Evan Rinehart; Victoria Jaeger; Konstantina Kyritsi; Linh Pham; Gianfranco Alpini; Heather Francis
Journal:  Lab Invest       Date:  2020-02-13       Impact factor: 5.662

4.  Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Authors:  Mette-Triin Purde; Rebekka Niederer; Nikolaus B Wagner; Stefan Diem; Fiamma Berner; Omar Hasan Ali; Dorothea Hillmann; Irina Bergamin; Markus Joerger; Martin Risch; Christoph Niederhauser; Tobias L Lenz; Martin Früh; Lorenz Risch; David Semela; Lukas Flatz
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-07       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.